Prospective KRAS assessment
Local assessment before inclusion, Validation by central assessment using allelic discrimination by TaqMan Probes, Applied Biosystems (P Laurent_Puig, Hôpital Européen Georges Pompidou, Paris)
Tumor evaluations (baseline then every 2 months) Clinical Biological (CEA marker) Radiological (CT-scan) 
KRAS assessment
Local KRAS assessment before inclusion (N=69) Tumour was centrally re-analyzed in eligible patients to confirm the KRAS WT status (targeted real time PCR Taqman probe approach) KRAS WT status confirmed in 56 patients (81.1%), A mutated version of the KRAS gene was found in 4 patients (6.5%) ; one was <10% tumour cell rich the 3 others >40%. Discrepancies were validated by second independent DNA extraction and analysis Tumor block was not available in 4 patients (6.5%), Tumor material was not sufficient (could not be amplified) in 1 patient (1.6%)
Hypothesis for false negative KRAS status
False negative results were from local test using sequencing Tumour cells were >40% in ¾ tumours suggesting at first sight the existence of a mutated subclone not detected by sequencing Quantification of the ratio mutated/WT allele by QPCR is not in favour of this hypothesis The robustness of targeted technologies using small size amplicons to detect genetic alterations in degraded DNAs from formalin fixed paraffin embedded samples could in part explain the discrepancies in this series. Finally 3/4 false negative samples were tested in the same laboratory 
Patient characteristics

WT KRAS confirmed (N=56)
G12D, N=2 G12C, N=1 G12V, N=1
KRAS status not evaluable (N=5)
Mutated KRAS (N=4) ITT analysis (N=61)
Tumor block not available (N=4) Tumor material not sufficient (N=1)
